ABT-737, Senolytic Bcl2 inhibitor (TBI3661)

Description

Product Details

Formal Name: 4-[4-[(4′-Chloro[1,1′-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]-benzamide

Molecular Formula: C₄₂H₄₅ClN₆O₅S₂

Formula Weight: 813.40

CAS Number: 852808-04-9

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 5 mg/ml)

Storage: -20°C

Stability: ≥ 2 years.

 

Applications

Senolytic Bcl2 inhibitor

 

Functions

Inhibitor of anti-apoptotic proteins from the Bcl family: Bcl-2, Bcl-X(L), and Bcl-w (Ki < 1 nM) that causes regression of solid tumors in mice. Senolytic agent which disrupts aberrant p21 expression, inducing apoptosis in senescent cells, and enhancing liver regeneration in mice. Acts synergistically to reduce cell viability when combined with CDK inhibitor purvalanol A in preclinical models of acute myeloid leukemia (AML).

 

Application Procedures

First dissolved in DMSO (up to 5 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

Additional information

SIZE (mg)	25 MG, 5 MG

Datasheet:

TBI3661_ABT-737

MSDS:

TBI3661_ABT-737_MSDS_2024